
Join to view full profile
David Chien M.D.Westlake Village, CA 91362
Dr. Chien is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- * https://www.linkedin.com/in/davidchienmd/ * https://www.krystalbio.com/about-us/leaders/
Education & Training
Johns Hopkins University School of MedicineFellowship, PET/CT, 2010 - 2011
Johns Hopkins UniversityResidency, Nuclear Medicine, 2007 - 2010
New York-Presbyterian/QueensInternship, Internal Medicine, 2006 - 2007
University of California, Davis, School of MedicineClass of 2006
Certifications & Licensure
CA State Medical License 2011 - 2027
NY State Medical License 2010 - 2012
PA State Medical License 2010 - 2012
American Board of Nuclear Medicine Nuclear Medicine- Certification Board of Nuclear CardiologyNuclear Cardiology
Awards, Honors, & Recognition
- National Research Service Award NIH, 2010
- Young Investigator Award Society of Nuclear Medicine, 2009
- Morton Levitt Research Award University of California Davis, 2004
Clinical Trials
- A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2012 May 21
- A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199
- A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199
Publications & Presentations
PubMed
- 16 citationsBempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.Arlene O Siefker-Radtke, Daniel C Cho, Adi Diab, Mario Sznol, Mehmet A Bilen
European Urology. 2022-10-01 - 24 citationsBempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.Nizar M Tannir, Daniel C Cho, Adi Diab, Mario Sznol, Mehmet A Bilen
Journal for Immunotherapy of Cancer. 2022-04-01 - 10 citationsPIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.Alexander Mm Eggermont, Paolo A Ascierto, Nikhil I Khushalani, Dirk Schadendorf, Genevieve Boland
Future Oncology. 2022-03-01
Abstracts/Posters
- Phase 1 preliminary safety, efficacy, and biomarker data from venetoclax (ABT-199/GDC-0199) + bendamustine and rituximab in R/R non-Hodgkin’s lymphomade Vos S, Swinnen L, Kozloff M, Wang D, Reid E, Nastoupil L, Fowler N, Cordero J, Gifford M, D’Amico D, Dunbar M, Zhu M, Agarwal S, Ross J, Punnoose E, McKeegan E, Hei..., Hematol Oncol, 1/1/2015
- A dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine and rituximab in patients with relapsed/refractory non-Hodgkin’s lymphomade Vos S, Flowers C, Wang D, Swinnen L, Fowler N, Reid E, Cordero J, Gifford M, D’Amico D, Dunbar M, Zhu M, Salem A, Heitner-Enschede S, Ricker JL, Chien D, Humerickho..., Haematologica, 1/1/2015
- Hypoxia [18F] HX4 PET imaging in patients with head and neck cancer: repeatability and stability during radiotherapyZegers C, Van Elmpt W, Hoebers F, Chien D, Lambini P, Radiotherapy and Oncology, 1/1/2015
Professional Memberships
- Member
External Links
- LinkedInhttps://www.linkedin.com/in/davidchienmd/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: